Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern
2009; Elsevier BV; Volume: 13; Issue: 4 Linguagem: Inglês
10.1016/j.jaapos.2009.06.003
ISSN1528-3933
Autores Tópico(s)Ocular Diseases and Behçet’s Syndrome
ResumoThe use of anti-vascular endothelial growth factor (VEGF) agents has dramatically changed the way we treat many retinal diseases.1-3 This paradigm shift in treatment is due to the ability of these drugs to inhibit VEGF, a molecule that has a pivotal role in a large variety of retinal conditions, including age-related macular degeneration (AMD), proliferative diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity (ROP), and many forms of retinal edema. Intravitreal ranibizumab (Lucentis; Genentech, San Francisco, CA) is currently FDA approved for the treatment of neovascular AMD.
Referência(s)